Citations

Clear

390 citation(s) found for "Loftus, E".

The Clinical Characteristics and Treatment Outcomes of Concomitant Eosinophilic Esophagitis and Inflammatory Bowel Disease
Urquhart, Siri A. , Quinn, Kevin P. , Loftus, Edward V. , Loftus, Edward V , Ravi, Karthik

Mayo Clinic

Crohn's & Colitis 360 | March 3, 2021 | Volume: 3 | Issue: 2 | Pages: No page available

10.1093/crocol/otab018 | PMID 36778939 Get It

Abstract Background The clinical characteristics and treatment outcomes in patients with eosinophilic esophagitis (EoE) and inflammatory bowel disease (IBD) have not been extensively investigated. Methods We determined treatment outcomes and frequencies of disease-related complications in patients with EoE and IBD. Results Among 69 patients who met inclusion criteria, 39 (56.5%) had a diagnosis of Crohn disease. Clinical and histologic response rates to proton pump inhibitors and topical steroids were 25.9% and 24.4%, respectively. Conclusions Lower than expected clinical and histologic response rates for EoE suggest the combination of EoE and IBD is a medically refractory phenotype with more difficult to treat EoE.
Ultrasound-guided transversus abdominis plane block vs trigger point injections for chronic abdominal wall pain: a randomized clinical trial
Moeschler, Susan M. , Pollard, E. Morgan, Pingree, Matthew J. , Bendel, Mark A., Mauck, William D. , Watson, James C. , Eldrige, Jason S. , Loftus, Conor G., Hooten, W. Michael , Mauck, W David, Pittelkow, Thomas P.

Mayo Clinic

Pain | January 14, 2021 | Volume: 162 | Issue: 6 | Pages: 1800-1805

10.1097/j.pain.0000000000002181 | PMID 33433147 Get It

Abstract The primary aim of this randomized clinical trial is to investigate the effects of ultrasound-guided transversus abdominis plane (TAP) vs ultrasound-guided trigger point injections (TPIs) on numerical rating scale pain scores at month 3 follow-up in patients with a chronic abdominal wall pain. The primary outcome measure was the difference in mean numeric rating scale pain scores between the TAP and TPI groups at month 3 in an intent-to-treat (ITT) analysis. A total of 60 patients were randomized 1:1 to receive an ultrasound-guided TAP block (n = 30) or an ultrasound-guided TPI (n = 30). No significant group differences in baseline demographic or clinical characteristics were observed. The mean baseline pain score for the TAP and TPI groups was 5.5 and 4.7, respectively. In the ITT analysis at month 3, the between-group difference in pain scores was 1.7 (95% confidence interval, 0.3-3.0) favoring the TPI group. In a secondary per-protocol analysis, the between-group difference in pain scores was 1.8 (95% confidence interval, 0.4-3.2) favoring the TPI group. For the ITT and per-protocol analyses, the group differences in pain scores were consistent with a medium effect size. The main finding of this randomized clinical trial is that adults with chronic abdominal wall pain who received a TPI reported significantly lower pain scores at month 3 follow-up compared with patients who received a TAP block.
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme
Winthrop, Kevin , Loftus, Edward V. , Baumgart, Daniel C. , Reinisch, Walter , Nduaka, Chudy I., Lawendy, Nervin, Chan, Gary , Mundayat, Rajiv , Friedman, Gary S. , Salese, Leonardo , Su, Chinyu , Loftus, Edward V , Reinisch, Walter , Thorpe, Andrew J

Mayo Clinic

Journal of Crohn's and Colitis | November 23, 2020 | Volume: 15 | Issue: 6 | Pages: 914-929

10.1093/ecco-jcc/jjaa233 | PMID 33245746 Get It

Abstract Background and Aims Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis. We report integrated analyses of infections in the Phase [P]2 and P3 OCTAVE programmes. Methods Three cohorts were analysed: Induction [P2/3 induction studies]; Maintenance [P3 maintenance study]; and Overall [all tofacitinib-treated patients in induction, maintenance, or ongoing, open-label, long-term extension studies; as of May 2019]. Proportions and incidence rates [IRs; unique patients with events/100 patient-years] of serious infections [SIs], herpes zoster [HZ] [non-serious and serious], and opportunistic infections [OIs] are reported [censored at time of event]. Results In the Induction Cohort [N = 1220], no patients receiving placebo and eight [0.9%] receiving tofacitinib 10 mg twice daily [BID] developed SIs. Maintenance Cohort [N = 592] SI IRs (95% confidence interval [CI]) were 1.94 [0.23–7.00] for placebo and 1.35 [0.16–4.87] and 0.64 [0.02–3.54] for tofacitinib 5 and 10 mg BID, respectively; HZ IRs were 0.97 [0.02–5.42], 2.05 [0.42–6.00], and 6.64 [3.19–12.22], respectively. In the Overall Cohort [N = 1157; 82.9% predominantly received tofacitinib 10 mg BID], SI, HZ, and non-HZ OI IRs were 1.70 [1.24–2.27], 3.48 [2.79–4.30], and 0.15 [0.04–0.38], respectively. No SIs resulted in death. Conclusions During induction, SIs were more frequent with tofacitinib versus placebo. SIs were generally infrequent in the Maintenance and Overall Cohorts, with rates comparable between treatment groups. Maintenance Cohort HZ IR was numerically higher with tofacitinib 10 mg BID versus 5 mg BID. Overall Cohort HZ IRs remained stable over time. Non-HZ OIs and viral infections were rare.
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos, Guilherme Piovezani , Dimopoulos, Christina , McDonald, Nicholas , Janssens, Laurens , Hung, Kenneth W, Proctor, Deborah D., Ruggiero, Elizabeth, Kane, Sunanda V. , Bruining, David H. , Faubion, William A. , Raffals, Laura E. , Loftus, Edward V. , Al‐Bawardy, Badr , McDonald, Nicholas M, Janssens, Laurens P, Loftus, Edward V , Ramos, Guilherme P , Janssens, Laurens P , Hung, Kenneth W

Mayo Clinic

Inflammatory Bowel Diseases | November 9, 2020 | Volume: 27 | Issue: 8 | Pages: 1270-1276

10.1093/ibd/izaa293 | PMID 33165569 Get It

Abstract Background There are limited data on how vedolizumab (VDZ) impacts extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD). The aim of this study was to determine the clinical outcomes of EIMs after initiation of VDZ for patients with IBD. Methods A multicenter retrospective study of patients with IBD who received at least 1 dose of VDZ between January 1, 2014 and August 1, 2019 was conducted. The primary outcome was the rate of worsening EIMs after VDZ. Secondary outcomes were factors associated with worsening EIMs and peripheral arthritis (PA) specifically after VDZ. Results A total of 201 patients with IBD (72.6% with Crohn disease; median age 38.4 years (interquartile range, 29-52.4 years); 62.2% female) with EIMs before VDZ treatment were included. The most common type of EIM before VDZ was peripheral arthritis (PA) (68.2%). Worsening of EIMs after VDZ occurred in 34.8% of patients. There were no statistically significant differences between the worsened EIM (n = 70) and the stable EIM (n = 131) groups in term of age, IBD subtype, or previous and current medical therapy. We found that PA was significantly more common in the worsening EIM group (84.3% vs 59.6%; P < 0.01). Worsening of EIMs was associated with a higher rate of discontinuation of VDZ during study follow-up when compared with the stable EIM group (61.4% vs 44%; P = 0.02). Treatment using VDZ was discontinued specifically because of EIMs in 9.5% of patients. Conclusions Almost one-third of patients had worsening EIMs after VDZ, which resulted in VDZ discontinuation in approximately 10% of patients. Previous biologic use or concurrent immunosuppressant or corticosteroid therapy did not predict EIM course after VDZ.
S0881 Therapeutic Drug Monitoring Dosing Regimen With Adalimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the SERENE-UC Maintenance Study
D’Haens, Geert , Louis, Édouard , Ferrante, Marc , Vogelsang, Harald, Mostafa, Nael M., Doan, Thao , Xie, Wangang, Petersson, Joel, Kalabic, Jasmina , Robinson, Anne, Sandborn, William J. , Colombel, Jean‐Frédéric , Panés, Julián , Schreiber, Stefan , Panaccione, Remo , Peyrin‐Biroulet, Laurent , Loftus, Edward V. , Danese, Silvio , Louis, Edouard , Armuzzi, Alessandro

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S454-S454

10.14309/01.ajg.0000705572.04908.5f Get It

S0875 Update on Clinical Outcome and Effectiveness of Corticosteroids in Patients With Crohn's Disease in a Population-Based Cohort
Bakhshi, Zeinab , Faubion, William A. , Tremaine, William, Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S450-S451

10.14309/01.ajg.0000705548.33925.67 Get It

S0830 The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Dimopoulos, Christina , Janssens, Laurens , Hung, Kenneth H., Proctor, Deborah D., Ruggiero, Elizabeth, Bruning, D. H., Faubion, William A. , Raffals, Laura E. , Janssens, Laurens P , Ramos, Guilherme Piovezani , McDonald, Nicholas , Bruning, David H., Loftus, Edward V. , Al‐Bawardy, Badr

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S427-S428

10.14309/01.ajg.0000705368.24314.98 Get It

S0819 Evaluating Cost Per Remission and Cost of Serious Adverse Events in Advanced Therapies for Ulcerative Colitis
Cohen, Russell D. , Candela, Ninfa , Lasch, Karen, Jairath, Vipul , Loftus, Edward V. , Schultz, Bob G.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S420-S421

10.14309/01.ajg.0000705324.95048.a6 Get It

S0665 Clostridium difficile Infection in Patients With Ulcerative Colitis Treated With Tofacitinib in the Ulcerative Colitis Program: An Update as of May 2019
Baumgart, Daniel C. , Kinnucan, Jami , Koram, Nana , Salese, Leonardo , Su, Chinyu , Woolcott, John , Loftus, Edward V. , Armuzzi, Alessandro , Curtis, Jeffrey R. , Kwok, Kenneth

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S333-S333

10.14309/01.ajg.0000704708.98059.7d Get It

S0663 Efficacy and Safety of Tofacitinib Retreatment for Ulcerative Colitis After Treatment Interruption: An Update of Results From the OCTAVE Clinical Trials
Dubinsky, Marla C. , Sharara, Ala I. , Lawendy, Nervin, Wang, Wenjin , Salese, Leonardo , Su, Chinyu , Modesto, Irene , Panés, Julián , Colombel, Jean‐Frédéric , Vermeire, Séverine , Guo, Xiang , Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S332-S332

10.14309/01.ajg.0000704700.92838.b3 Get It